PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery · 12.05.2026 · 1-12
DOI: 10.1159/000552426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive Surgery, online erschienen am 12.05.2026. Verfasst von Arianna Castagna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Pressurized Intraperitoneal Aerosol Chemotherapy, Mesothelioma, Lung Neoplasms. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, but this approach is limited to selected patients. Summary: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged as a novel technique improving drug delivery and penetration in the peritoneal cavity. This narrative review evaluates the role of PIPAC in the treatment of MPM, analysing data from clinical studies on its feasibility, safety, and efficacy. Evidence suggests that PIPAC is a well-tolerated procedure, with a manageable safety profile and potential to improve survival and tumour response in patients with unresectable or recurrent disease. Limitations in current studies include small cohorts and heterogeneous patient populations, underscoring the need for further research. Key Message: PIPAC represents a promising therapeutic option, offering enhanced intraperitoneal chemotherapy delivery with minimal systemic toxicity. Future investigations should focus on optimizing treatment protocols and evaluating long-term benefits to better define PIPAC’s role in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany.
- Department of General, Visceral and Tumour Surgery, Northwest Hospital, Frankfurt, Germany.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
- Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany, andreas.brandl@med.uni-heidelberg.de.
- Department of General, Visceral and Tumour Surgery, Northwest Hospital, Frankfurt, Germany, andreas.brandl@med.uni-heidelberg.de.
Zitieren
APA
Castagna, A., Fotiadou, A., Ramouz, A., Gesheva, P., Brindl, N., Solass, W., & Brandl, A. (2026). PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions. Digestive Surgery, 1-12. https://doi.org/10.1159/000552426
Vancouver
Castagna A, Fotiadou A, Ramouz A, Gesheva P, Brindl N, Solass W, et al. PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions. Digestive Surgery. 2026:1-12. doi:10.1159/000552426
BibTeX
@article{Castagna2026,
author = {Castagna, Arianna and Fotiadou, Aphrodite and Ramouz, Ali and Gesheva, Preslava and Brindl, Niall and Solass, Wiebke and Brandl, Andreas},
title = {PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions},
journal = {Digestive Surgery},
year = {2026},
pages = {1--12},
doi = {10.1159/000552426}
}
EUVIMED